title: Bactericidal activities of HMR 3647, moxifloxacin, and rifapentine against Mycobacterium leprae in mice.
abstract: Bactericidal activities of HMR 3647 (HMR), moxifloxacin (MXFX), and rifapentine (RPT) against Mycobacterium leprae, measured by the proportional bactericidal technique in the mouse footpad system, were compared with those of the established antileprosy drugs clarithromycin (CLARI), ofloxacin (OFLO), and rifampin (RMP). Administered in five daily doses of 100 mg/kg of body weight, HMR appeared slightly more bactericidal than CLARI. In a single dose, MXFX at 150 mg/kg was more active than the same dose of OFLO and displayed exactly the same level of activity as RMP at 10 mg/kg; the combination MXFX-minocycline (MINO) (MM) was more bactericidal than the combination OFLO-MINO (OM); RPT at 10 mg/kg was more bactericidal than the same dose of RMP and even more active than the combination RMP-OFLO-MINO (ROM); the combination RPT-MXFX-MINO (PMM) killed 99.9% of viable M. leprae and was slightly more bactericidal than RPT alone, indicating that the combination PMM showed an additive effect against M. leprae.
authors.affiliation: Faculté de Medecine Pitié-Salpêtrière, Paris, France.
authors.forename: S
authors.initials: S
authors.lastname: Consigny
authors.forename: A
authors.initials: A
authors.lastname: Bentoucha
authors.forename: P
authors.initials: P
authors.lastname: Bonnafous
authors.forename: J
authors.initials: J
authors.lastname: Grosset
authors.forename: B
authors.initials: B
authors.lastname: Ji
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000890:Anti-Infective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001372:Aza Compounds; D005260:Female; D024841:Fluoroquinolones; D005528:Foot / Q000382:microbiology; D048628:Ketolides; D007917:Leprostatic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D007918:Leprosy / Q000188:drug therapy* / Q000382:microbiology; D018942:Macrolides; D051379:Mice; D008826:Microbial Sensitivity Tests; D000077266:Moxifloxacin; D009166:Mycobacterium leprae / Q000187:drug effects*; D011804:Quinolines; D012293:Rifampin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D012867:Skin / Q000382:microbiology
chemical_list: D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D048628:Ketolides; D007917:Leprostatic Agents; D018942:Macrolides; D011804:Quinolines; C106791:telithromycin; D000077266:Moxifloxacin; D012293:Rifampin; C018421:rifapentine